Meeting the Global Demand for CAR T-cell Therapies

The demand for CAR T-cell therapies is growing rapidly, but traditional manufacturing methods are struggling to keep up. They’re labour-intensive, slow to scale, and come with high costs that limit patient access.

At BioOra, we’re changing the model. By automating CAR T-cell production on a closed, GMP-licensed platform, we can enable a faster, more scalable path from clinical trial to commercial supply—without compromising safety, quality, or efficacy.

In partnership with leading clinical and research institutions, including the Malaghan Institute of Medical Research, we’re integrating advanced manufacturing with world-class models of care to accelerate the delivery of life-saving therapies.

Our current investment will support:

• Ongoing development and expansion of our semi-automated manufacturing platform

• Construction of New Zealand’s first dedicated CAR T-cell manufacturing facility

• Continued R&D and the investigation of new CAR T-cell constructs

We’re building the future of cancer treatment, right here in New Zealand.